News - Pfizer, Research

Filter

Current filters:

PfizerResearch

Popular Filters

1 to 25 of 101 results

Pfizer’s tofacitinib meets primary endpoints in Ph III psoriasis study

26-05-2014

US pharma giant Pfizer on Friday announced positive results from the Oral treatment Psoriasis Trial (OPT)…

Anti-Arthritics/RheumaticsDermatologicalsPfizerPharmaceuticalResearchtofacitinib

BioRestorative Therapies enters research accord with Pfizer

22-05-2014

US stem-cell therapies developer BioRestorative Therapies has entered into a two-year collaborative research…

BioRestorative TherapiesBiotechnologyLicensingMetabolicsPfizerResearch

Greater brand-drug adoption fuels Asia-Pacific breast cancer market

09-05-2014

Due to an increasing uptake of branded drugs in Asia-Pacific (APAC), the region’s breast cancer therapeutics…

afatinibAsia-PacificBoehringer IngelheimEisaiHalavenKadcylaMarkets & MarketingneratinibOncologypalbociclibPerjetaPfizerPharmaceuticalResearchRoche

AstraZeneca sets out its value stall, projecting annual revenues of $45 billion by 2023

AstraZeneca sets out its value stall, projecting annual revenues of $45 billion by 2023

06-05-2014

In a bid to explain its rejection of US pharma giant Pfizer’s increased takeover bid for the Anglo-Swedish…

AstraZenecaFinancialMergers & AcquisitionsPfizerPharmaceuticalResearch

Potential to fast-track drugs in new Cancer Research UK partnership with AstraZeneca and Pfizer

Potential to fast-track drugs in new Cancer Research UK partnership with AstraZeneca and Pfizer

17-04-2014

British charity Cancer Research UK has joined forces with Anglo-Swedish drug major AstraZeneca and US…

AstraZenecaCancerHealthMajorMedicineOncologyPfizerPharmaceuticalPharmacologyResearchUK

Pfizer palbociclib trial disappoints, despite meeting primary endpoint

Pfizer palbociclib trial disappoints, despite meeting primary endpoint

08-04-2014

At the American Association of Cancer Research (AACR) Annual Meeting 2014 in San Diego, US pharma giant…

AmgenOncologypalbociclibPfizerPharmaceuticalResearch

EMD Serono, Pfizer and Broad Institute link up on lupus research

EMD Serono, Pfizer and Broad Institute link up on lupus research

01-04-2014

EMD Serono, a US subsidiary of Germany’s Merck KGaA, has signed a research agreement with US pharma…

Anti-Arthritics/RheumaticsEMD SeronoMerck KGaAPfizerPharmaceuticalResearch

Pfizer’s Xalkori meets PFS endpoints in untreated NSCLC patients

Pfizer’s Xalkori meets PFS endpoints in untreated NSCLC patients

25-03-2014

US pharma behemoth Pfizer says that PROFILE 1014, a Phase III study of anaplastic lymphoma kinase (ALK)…

OncologyPfizerPharmaceuticalResearchXalkori

Mixed Ph III data for Pfizer’s tofacitinib vs Enbrel in plaque psoriasis

24-03-2014

US pharma giant Pfizer has announced detailed results from OPT Compare (A3921080), a Phase III study…

DermatologicalsEnbrelPfizerPharmaceuticalResearchtofacitinibXeljanz

Actelion says COMPASS-2 bosentan study fails primary endpoint

Actelion says COMPASS-2 bosentan study fails primary endpoint

17-03-2014

Europe’s largest biotech company Actelion has announced disappointing results of COMPASS-2, a Phase…

ActelionBiotechnologybosentanPfizerResearchRespiratory and PulmonarysildenafilTracleer

Positive top-line results for Pfizer’s Prevenar 13 in pneumonia in over 65s

25-02-2014

US pharma behemoth Pfizer says that top-line results from a study of Prevenar 13 (pneumococcal 13-valent…

Antibiotics and Infectious diseasesPfizerPharmaceuticalPrevenarResearchVaccines

Strong mid-stage trial results for Pfizer’s palbociclib in advanced breast cancer

Strong mid-stage trial results for Pfizer’s palbociclib in advanced breast cancer

03-02-2014

Positive results from a randomized Phase II trial [PALOMA-1] of US pharma giant Pfizer’s palbociclib…

OncologypalbociclibPfizerPharmaceuticalResearch

Pfizer’s dacomitinib fails in two late-stage NSCLC studies

Pfizer’s dacomitinib fails in two late-stage NSCLC studies

28-01-2014

US pharma giant Pfizer has released disappointing top-line results from two randomized Phase III studies…

dacomitinibOncologyPfizerPharmaceuticalResearch

Pfizer’s ALO-02 meets efficacy endpoint in Ph III

Pfizer’s ALO-02 meets efficacy endpoint in Ph III

23-01-2014

US pharma behemoth Pfizer has released top-line results from a Phase III study of ALO-02 (oxycodone HCl…

ALO-02NeurologicalPfizerPharmaceuticalResearch

Pfizer tasked with novel vaccine research by US government department

Pfizer tasked with novel vaccine research by US government department

12-12-2013

Pfizer, the world’s largest drugmaker by sales, has been awarded a nearly $7.7 million technology investment…

North AmericaPfizerPharmaceuticalResearchVaccines

Puma Biotech rockets on positive results with neratinib in I-SPY 2 TRIAL

06-12-2013

USA-based development-stage firm Puma Biotechnology saw its shares leap 42% to nearly $66 in morning…

BiotechnologyneratinibOncologyPfizerPuma BiotechResearch

Pfizer and GSK link up to trial combo melanoma therapy

Pfizer and GSK link up to trial combo melanoma therapy

22-11-2013

Two of the world’s pharma giants, USA-based Pfizer and the UK’s GlaxoSmithKline have joined forces…

GlaxoSmithKlineMekinistOncologypalbociclibPfizerPharmaceuticalResearchtrametinib

Pharma figures high in EU R&D Investment Scoreboard, but led by US firms

19-11-2013

Though not topping the league table, the pharmaceutical industry had a number of drugmakers among the…

EuropeFinancialGlaxoSmithKlineJohnson & JohnsonMerck & CoNorth AmericaNovartisPfizerPharmaceuticalResearchRocheSanofi

Pfizer says Rapamune failed endpoints in renal transplant study

Pfizer says Rapamune failed endpoints in renal transplant study

09-11-2013

US pharma behemoth Pfizer released disappointing top-line results from a Phase IIIb/IV study of its already-marketed…

ImmunologicalsPfizerPharmaceuticalRapamuneResearch

Pfizer to continue Remoxy pain relief development

Pfizer to continue Remoxy pain relief development

24-10-2013

US pharma giant Pfizer will continue the development program for Remoxy Extended-Release Capsules CII,…

AnalgesiaNorth AmericaPfizerPharmaceuticalRemoxyResearch

Mixed results for Pfizer’s two Lyrica Phase IIIb studies

Mixed results for Pfizer’s two Lyrica Phase IIIb studies

21-10-2013

Pfizer has announced mixed results from two Phase IIIb studies of Lyrica capsules CV in patients with…

AnalgesiaLyricaNorth AmericaPfizerPharmaceuticalResearch

Pfizer sees mixed top-line results in the first two of five phase III clinical trials of tofacitinib

Pfizer sees mixed top-line results in the first two of five phase III clinical trials of tofacitinib

09-10-2013

Pfizer has announced mixed top-line results from two Phase III clinical trials of tofacitinib for the…

DermatologicalsNorth AmericaPfizerPharmaceuticalResearchtofacitinibXeljanz

Karo Bio gets first milestone in Pfizer collaboration

06-09-2013

Under its collaboration with US pharma behemoth Pfizer (NYSE: PFE), Sweden's Karo Bio (STO: KARO) says…

Anti-Arthritics/RheumaticsDermatologicalsFinancialKaro BioLicensingNeurologicalPfizerPharmaceuticalResearch

Oxford BioMedica earns Pfizer milestone

28-08-2013

UK, gene-based biopharma company Oxford BioMedica (LSE: OXB) says it has received a $1 million milestone…

BiotechnologyFinancialOncologyOxford BioMedicaPF-06263507PfizerResearch

1 to 25 of 101 results

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top